Register
Login:
Share:
Email Facebook Twitter




Summit Ther Share Price (SUMM)



Share Price Information for Summit Ther (SUMM)


Share Price: 115.00Bid: 110.00Ask: 120.00Change: 0.00 (0.00%)No Movement on Summit Ther
Spread: 10.00Spread as %: 9.09%Open: 115.00High: 115.00Low: 115.00Yesterday’s Close: 115.00

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
115.00

Share Price SpacerBid
110.00

Share Price SpacerAsk
120.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
10,999

Share Price SpacerOpen
115.00

Share Price SpacerHigh
115.00

Share Price SpacerLow
115.00

Share Price SpacerClose
115.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 61.47m £70.69m 2,000

52 Week High 172.50 52 Week High Date 17-AUG-2015
52 Week Low 82.50 52 Week Low Date 4-MAR-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
4 9,098 1,901 -3.966 -29.00 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

27-May-16
12:33:58
116.50
385
Buy* 
110.00
120.00
448.53
Trade Type:
Ordinary

27-May-16
11:55:20
110.25
9,098
Sell* 
110.00
120.00
10.03k
Trade Type:
Ordinary

27-May-16
09:38:08
116.55
1,500
Buy* 
110.00
120.00
1,748
Trade Type:
Ordinary




View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
2.33USD7,5007500
17-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
2.3USD10,50010500
16-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
2.34USD4,25014442
View more Summit Ther directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Sat 14:06GP68Summit's Message Board on Yahoo USA115.00No Opinion
Brilliant work AMM. Well done. Looks like you are having to do our Cambs, Mass office work for them. Hmmmmm 'Cranks and Weirdos' sounds like a few I have come across around the AIM message boards! GLA
Sat 11:53AppleMacManSummit's Message Board on Yahoo USA115.00No Opinion
Yesterday I decided to engage in a wee sortie on SAREPTA’s american Yahoo Finance message board in order to gauge the level of awareness of Summit’s DMD drug. I was surprised by the response (given the mess SRPT are currently in with the FDA approval / rejection postponed) … there was actually some polite banter with calm and collected P.I.’s who are heavily invested in Sarepta. Interestingly my straw pole suggests that some do actually have a small Summit investment but… Read More
Fri 09:21gmccRE: Ridinilazole (SMT19969)115.00No Opinion
Yes thought this trial would be more advanced unfortunately par for the course with Summit yet another trial delayed , albeit to be fair they have not given it much publicity , just as well c-diff sale not dependent on Fidaxomicin comparison data outcomes !!
Fri 09:20doubleup888RE: Ridinilazole (SMT19969)115.00No Opinion
Sounds like a waste of money if it's just to show how confident they are, if they don't need the additional data for a deal.
Fri 07:59Free-MoneyRE: Ridinilazole (SMT19969)115.00No Opinion
As I understand it we've been told they expect the top line results from this study in Q3 now.

Also we've been told that any deal negotiations will not be waiting for this study. I assume they already have enough data to prove commercial value. The data shows Ridinilazole should be used as 1st and 2nd line treatment.

The study with Fidaxomicin is just a demonstration of their confidence that Ridinilazole can be compared to the current very best in class for efficacy as I see it. GLA
Thu 22:59gmccRE: Ridinilazole (SMT19969)115.00No Opinion
Note 16 site locations UK 7 –USA 5- Czech Republic 4 ,only 1 (UK ) site active but majority are now recruiting ?

Interesting expansion of sites ?

Previous trial info :

https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-005483-25/GB

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Summit Ther (SUMM) >>

Please login or register to post a message on Share Chat.






Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.